- Home
- PX vs NVCR Comparison
PX vs NVCR Comparison
Compare PX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PX
- NVCR
- Stock Information
- Founded
- PX 1992
- NVCR 2000
- Country
- PX United States
- NVCR Switzerland
- Employees
- PX N/A
- NVCR 1488
- Industry
- PX Investment Managers
- NVCR Medical/Dental Instruments
- Sector
- PX Finance
- NVCR Health Care
- Exchange
- PX Nasdaq
- NVCR Nasdaq
- Market Cap
- PX 1.4B
- NVCR 1.4B
- IPO Year
- PX 2021
- NVCR 2015
- Fundamental
- Price
- PX $11.96
- NVCR $12.72
- Analyst Decision
- PX Buy
- NVCR Buy
- Analyst Count
- PX 7
- NVCR 7
- Target Price
- PX $14.64
- NVCR $28.79
- AVG Volume (30 Days)
- PX 384.7K
- NVCR 1.3M
- Earning Date
- PX 11-06-2025
- NVCR 10-29-2025
- Dividend Yield
- PX 1.25%
- NVCR N/A
- EPS Growth
- PX 640.39
- NVCR N/A
- EPS
- PX 0.13
- NVCR N/A
- Revenue
- PX $299,628,000.00
- NVCR $630,160,000.00
- Revenue This Year
- PX $4.33
- NVCR $6.68
- Revenue Next Year
- PX $17.44
- NVCR $7.01
- P/E Ratio
- PX $93.70
- NVCR N/A
- Revenue Growth
- PX 15.60
- NVCR 14.58
- 52 Week Low
- PX $8.85
- NVCR $10.87
- 52 Week High
- PX $14.28
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- PX 45.14
- NVCR 53.05
- Support Level
- PX $11.92
- NVCR $11.98
- Resistance Level
- PX $12.55
- NVCR $12.83
- Average True Range (ATR)
- PX 0.31
- NVCR 0.56
- MACD
- PX -0.06
- NVCR 0.16
- Stochastic Oscillator
- PX 15.43
- NVCR 53.43
About PX P10 Inc.
P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.